Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads againstMycobacterium tuberculosis
Lists
Only you see this
Abstract
A potent, noncytotoxic indazole sulfonamide was identified by high-throughput screening of >100,000 synthetic compounds for activity against Mycobacterium tuberculosis (Mtb). This noncytotoxic compound did not directly inhibit cell wall biogenesis but triggered a slow lysis of Mtb cells as measured by release of intracellular green fluorescent protein (GFP). Isolation of resistant mutants followed by whole-genome sequencing showed an unusual gene amplification of a 40 gene region spanning from Rv3371 to Rv3411c and in one case a potential promoter mutation upstream of guaB2 (Rv3411c) encoding inosine monophosphate dehydrogenase (IMPDH). Subsequent biochemical validation confirmed direct inhibition of IMPDH by an uncompetitive mode of inhibition, and growth inhibition could be rescued by supplementation with guanine, a bypass mechanism for the IMPDH pathway. Beads containing immobilized indazole sulfonamides specifically interacted with IMPDH in cell lysates. X-ray crystallography of the IMPDH-IMP-inhibitor complex revealed that the primary interactions of these compounds with IMPDH were direct pi-pi interactions with the IMP substrate. Advanced lead compounds in this series with acceptable pharmacokinetic properties failed to show efficacy in acute or chronic murine models of tuberculosis (TB). Time-kill experiments in vitro suggest that sustained exposure to drug concentrations above the minimum inhibitory concentration (MIC) for 24 h were required for a cidal effect, levels that have been difficult to achieve in vivo. Direct measurement of guanine levels in resected lung tissue from tuberculosis-infected animals and patients revealed 0.5-2 mM concentrations in caseum and normal lung tissue. The high lesional levels of guanine and the slow lytic, growth-rate-dependent effect of IMPDH inhibition pose challenges to developing drugs against this target for use in treating TB.
BibTeX
@inproceedings{park2016essential,
author = {Yumi Park and A. Pacitto and Tracy Bayliss and Laura A. T. Cleghorn and Zhe Wang and Travis Hartman and Kriti Arora and Thomas R. Ioerger and J.C. Sacchettini and Menico Rizzi and Stefano Donini and Tom L. Blundell and David B. Ascher and Kyu Y. Rhee and Ardala Breda and Nian Zhou and Véronique Dartois and Surendranadha Reddy Jonnala and Laura E. Via and Valerie Mizrahi and Ola Epemolu and Laste Stojanovski and Fred Simeons and Maria Osuna‐Cabello and Lucy C.J. Ellis and Claire J. Mackenzie and Alasdair Smith and Susan H. Davis and Dinakaran Murugesan and Kirsteen Buchanan and Penelope A. Turner and Margaret Huggett and Fabio Zuccotto and María José Rebollo-López and María José Lafuente-Monasterio and Olalla Sanz and Gracia Santos Diaz and Joël Lelièvre and Lluís Ballell and Carolyn Selenski and Matthew Axtman and Sonja Ghidelli‐Disse and Hannah Pflaumer and Markus Bösche and Gerard Drewes and Gail M. Freiberg and Matthew D. Kurnick and Myron Srikumaran and Dale J. Kempf and Simon R. Green and Peter C. Ray and Kevin D. Read and Paul G. Wyatt and Clifton E. Barry and Helena I. Boshoff},
title = {{Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against<i>Mycobacterium tuberculosis</i>}},
booktitle = {ACS},
year = {2016},
doi = {10.1021/acsinfecdis.6b00103},
}Loading related content...